• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [20545 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2022     Health Technology Wales (HTW) Extreme hypofractionated radiotherapy (EHFRT) for localised prostate cancer
2022     Health Technology Wales (HTW) Convalescent plasma therapy for the treatment of COVID-19
2022     Austrian Institute for Health Technology Assessment (AIHTA) Lower esophageal sphincter devices for laparoscopic surgery in patients with gastroesophageal reflux disease (GERD)
2022     Austrian Institute for Health Technology Assessment (AIHTA) Chemosaturation with percutaneous hepatic perfusion for patients with liver cancer
2022     Austrian Institute for Health Technology Assessment (AIHTA) His-bundle-pacing for patients requiring a permanent pacemaker or cardiac resynchronisation
2022     Austrian Institute for Health Technology Assessment (AIHTA) Microwave ablation for liver tumours
2022     Austrian Institute for Health Technology Assessment (AIHTA) Hepatic and portal vein embolisation prior to major hepatectomy
2022     Austrian Institute for Health Technology Assessment (AIHTA) Percutaneous transvascular implantation of a coronary sinus reducing stent. Update 2022
2022     Austrian Institute for Health Technology Assessment (AIHTA) Subcutaneous implantable cardioverter-defibrillator (S-ICD). Update 2022
2022     Austrian Institute for Health Technology Assessment (AIHTA) Upper airway stimulation for moderate-to-severe sleep apnoea. Update 2022
2022     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Effectiveness of non-pharmacological interventions aimed at workplaces in controlling the spread of COVID-19]
2022     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Effectiveness of non-pharmacological interventions aimed at commerce in controlling the spread of COVID-19]
2022     Austrian Institute for Health Technology Assessment (AIHTA) Percutaneous coronary interventions (PCI) for chronic total occlusion (CTO). Update 2022
2022     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Portable home hemodialysis systems]
2022     Center for Drug Evaluation (CDE) The reimbursement coverage decisions and pricing rules for medical devices in Taiwan
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: issues pertaining to the implementation of a clinical decision support system for diagnostic test ordering]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: service trajectories and services for at risk or neglected children and their families]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: update of the optimal usage guide on sexually transmitted and blood borne infections – confirmed Mycoplasma genitalium infection]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: Hereditary Cardiovascular diseases NGS Panel - Evaluation report on the repatriation of an analysis carried out outside of the province of Québec]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: use of microsurgery for the prevention and treatment of cancer-related lymphedema]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: risks of hospitalization and death related to COVID-19 in people with intellectual disabilities (ID) or autism spectrum disorder (ASD)]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: risks of hospitalization and death related to COVID-19 in people with physical disabilities using rehabilitation services]
2022     NIHR Health Services and Delivery Research programme Perioperative exercise programmes to promote physical activity in the medium to long term: systematic review and qualitative research
2022     NIHR Health Technology Assessment programme Deprescribing medicines in older people living with multimorbidity and polypharmacy: the TAILOR evidence synthesis
2022     Institute for Clinical and Economic Review (ICER) Tirzepatide for type 2 diabetes
2022     Institute for Clinical and Economic Review (ICER) Special assessment of outpatient treatments for COVID-19
2022     Institute for Clinical and Economic Review (ICER) Betibeglogene autotemcel for beta thalassemia: effectiveness and value
2022     Health Information and Quality Authority (HIQA) Health technology assessment of metabolic surgery for the treatment of comorbid type 2 diabetes and obesity
2022     Agency for Care Effectiveness (ACE) Osimertinib for treating EGFR mutation-positive non-small-cell lung cancer
2022     Agency for Care Effectiveness (ACE) Review of cancer drugs for chronic lymphocytic leukaemia
2022     Agency for Care Effectiveness (ACE) Acalabrutinib, bortezomib and ibrutinib for treating mantle cell lymphoma
2022     Agency for Care Effectiveness (ACE) Daratumumab-based regimens for newly diagnosed multiple myeloma
2022     Agency for Care Effectiveness (ACE) Polatuzumab vedotin for treating relapsed or refractory diffuse large B-cell lymphoma
2022     Agency for Care Effectiveness (ACE) Poly (ADP-ribose) polymerase inhibitors for treating BRCA-mutated, HER2-negative advanced breast cancer
2022     Agency for Care Effectiveness (ACE) Review of cancer drugs for treating early or advanced HER2-positive breast cancer
2022     Agency for Care Effectiveness (ACE) Ruxolitinib for treating polycythaemia vera
2022     Agency for Care Effectiveness (ACE) Review of cancer drugs for treating advanced urothelial carcinoma
2022     Agency for Care Effectiveness (ACE) Brentuximab vedotin for treating T-cell lymphoma
2022     Agency for Care Effectiveness (ACE) Negative pressure wound therapy for wound management in patients with diabetes (type 1 and 2)
2022     Norwegian Institute of Public Health (NIPH) [Overdose warning systems: a single technology assessment - mapping]
2022     Norwegian Institute of Public Health (NIPH) [Transcranial direct current stimulation for depression and aphasia. A health technology assessment]
2022     Ontario Health Mechanical thrombectomy for acute and subacute blocked arteries and veins in the lower limbs
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: efficacy of psychosocial interventions for the prevention and treatment of common mental disorders and symptoms]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: Evaluation of Fibryga (human fibrinogen concentrate) – acquired fibrinogen deficiency]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: molecular profiling of adult solid tumors - Focus Panel (Illumina) – 52 somatic biomarkers analysis]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: helicopter emergency medical services (HEMS) - needs analysis and clientele identification]
2022     Agency for Care Effectiveness (ACE) Emicizumab prophylaxis for patients with haemophilia A
2022     Agency for Care Effectiveness (ACE) Sitagliptin for treating type 2 diabetes mellitus
2022     Agency for Care Effectiveness (ACE) Tofacitinib, ustekinumab and vedolizumab for treating inflammatory bowel disease
2022     Agency for Care Effectiveness (ACE) Bevacizumab biosimilar for treating different types of cancers
2022     Agency for Care Effectiveness (ACE) PARP inhibitors and bevacizumab for treating advanced ovarian cancer
2022     Agency for Care Effectiveness (ACE) Carbonic anhydrase inhibitor eye drops for treating open-angle glaucoma or ocular hypertension
2022     Agency for Care Effectiveness (ACE) Aflibercept, bevacizumab and ramucirumab for treating metastatic colorectal cancer
2022     Agency for Care Effectiveness (ACE) Bevacizumab for treating persistent, recurrent or metastatic cervical cancer
2022     Agency for Care Effectiveness (ACE) High-strength insulin glargine for treating type 1 and 2 diabetes mellitus
2022     Agency for Care Effectiveness (ACE) Review of cancer drugs for previously treated advanced hepatocellular carcinoma
2022     Agency for Care Effectiveness (ACE) Botulinum toxin type A for the prophylaxis of headaches in adults with chronic migraine
2022     Agency for Care Effectiveness (ACE) Regorafenib and trifluridine/tipiracil for previously treated metastatic colorectal cancer
2022     Agency for Care Effectiveness (ACE) Ranibizumab for treating age-related macular degeneration, diabetic macular oedema and retinal vein occlusion
2022     Agency for Care Effectiveness (ACE) Lenvatinib and sorafenib for treating advanced hepatocellular carcinoma
2022     Agency for Care Effectiveness (ACE) Everolimus, lanreotide, octreotide and sunitinib for treating advanced neuroendocrine tumours
2022     Agency for Care Effectiveness (ACE) Review of cancer drugs for previously treated multiple myeloma
2022     Agency for Care Effectiveness (ACE) Immune checkpoint inhibitors and BRAK/MEK inhibitors for treating advanced malignant melanoma
2022     Agency for Care Effectiveness (ACE) Lenvatinib and sorafenib for treating differentiated thyroid cancer
2022     Agency for Care Effectiveness (ACE) Eltrombopag for treating immune thrombocytopenia and severe aplastic anaemia
2022     Agency for Care Effectiveness (ACE) Dabrafenib in combination with trametinib for treating BRAF V600 mutation-positive anaplastic thyroid cancer
2022     Agency for Care Effectiveness (ACE) Regorafenib and sunitinib for treating advanced gastrointestinal stromal tumours
2022     Agency for Care Effectiveness (ACE) Cetuximab and panitumumab for treating RAS wild-type colorectal cancer
2022     Agency for Care Effectiveness (ACE) Review of cancer drugs for prostate cancer
2022     Agency for Care Effectiveness (ACE) Tyrosine kinase inhibitors for treating ALK mutation-positive advanced non-small-cell lung cancer
2022     Agency for Care Effectiveness (ACE) Update of MOH list of subsidised drugs to include treatments for various cancer conditions
2022     Agency for Care Effectiveness (ACE) Review of cancer drugs for previously treated advanced gastric cancer
2022     Agency for Care Effectiveness (ACE) Tyrosine kinase inhibitors, immune checkpoint inhibitors and everolimus for treating advanced renal cell cancer
2022     Agency for Care Effectiveness (ACE) Long-acting erythropoiesis-stimulating agents for treating anaemia in chronic kidney disease
2022     Agency for Care Effectiveness (ACE) Review of cancer drugs for acute lymphoblastic leukaemia
2022     Agency for Care Effectiveness (ACE) Disease-modifying therapies for treating multiple sclerosis
2022     Agency for Care Effectiveness (ACE) Biologics and Janus kinase inhibitors after conventional disease modifying antirheumatic drugs for treating rheumatoid arthritis
2022     Agency for Care Effectiveness (ACE) Infliximab biosimilar for treating inflammatory conditions
2022     Agency for Care Effectiveness (ACE) Sacubitril/valsartan for treating chronic heart failure with reduced ejection fraction
2022     Agency for Care Effectiveness (ACE) Non-vitamin K antagonist oral anti-coagulation agents (NOACs) for the treatment and secondary prevention of venous thromboembolism
2022     Agency for Care Effectiveness (ACE) Non-vitamin K antagonist oral anti-coagulation agents (NOACs) for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation
2022     Agency for Care Effectiveness (ACE) Denosumab for treating osteoporosis and glucocorticoid-associated bone loss
2022     Agency for Care Effectiveness (ACE) Coronary intravascular lithotripsy for patients with severely calcified, stenotic de novo coronary artery
2022     Agency for Care Effectiveness (ACE) Bone conduction hearing implants for patients with single sided deafness
2022     Agency for Care Effectiveness (ACE) Active middle ear implants for patients with hearing loss
2022     Agency for Care Effectiveness (ACE) Bone conduction hearing implants for patients with conductive or mixed hearing loss
2022     Agency for Care Effectiveness (ACE) Continuous subcutaneous insulin infusion therapy for treating type 1 diabetes
2022     Agency for Care Effectiveness (ACE) Percutaneous vertebral augmentation systems for treating patients with vertebral compression fractures
2022     Agency for Care Effectiveness (ACE) Bilateral cochlear implants for children with severe-to-profound sensorineural hearing loss in both ears
2022     Agency for Care Effectiveness (ACE) Overview of clinical applications of telemedicine
2022     Agency for Care Effectiveness (ACE) 3D printing and its clinical applications
2022     Agency for Care Effectiveness (ACE) Artificial intelligence and its clinical applications
2022     Agency for Care Effectiveness (ACE) The PrecivityAD test for the prognosis of Alzheimer's disease
2022     Agency for Care Effectiveness (ACE) Caption guidance to guide image acquisition in point-of-care echocardiography for patients with cardiovascular disease
2022     Agency for Care Effectiveness (ACE) Vagus nerve stimulation with the VITARIA System for heart failure with reduced ejection fraction
2022     Agency for Care Effectiveness (ACE) Revivent TC transcatheter ventricular enhancement system for ischemic heart failure
2022     Scottish Health Technologies Group (SHTG) Chest wall bracing for children and young people with pectus carinatum
2022     Scottish Health Technologies Group (SHTG) Minuteful Kidney for home testing of albumin-to-creatine ratio (ACR)
2022     NIHR Health Services and Delivery Research programme Safety of disinvestment in mid- to late-term follow-up post primary hip and knee replacement: the UK SAFE evidence synthesis and recommendations
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: solid organ transplantation – Section 1 - overview of heart and lung transplantation in Québec]